Periodontal disease (PD) is a chronic disorder of the tissues which surround and support the teeth which, if untreated, will progress to compromise tooth function and lead to tooth loss. Early-onset periodontal diseases (EOP) comprise a sub-group of PD with a particularly aggressive clinical course characterised classically by localised or generalised loss of alveolar bone early in life. 1 Genetic factors seem to have a strong influence on susceptibility to EOP as evidenced by population and family studies. 2 The prevalence of EOP amongst white Caucasians is only 0.1%. 3 Nevertheless there has been considerable interest in the study of EOP since these may reveal factors and in particular genetic variants which also influence the host response in PD and other common disorders with an inflammatory pathogenesis.
Interleukin-10 (IL-10) is a major immunoregulatory cytokine which is important not only because it has a number of biological effects, but because it is produced by a variety of immune and other cells. 4 An IL-10 dependent CD4
+ T cell subset termed the T-regulatory 1 (Tr1) cell which is capable of suppressing antigen-specific immune responses and actively down-regulates pathological immune responses in vivo has been described. 5 Thus IL-10 is generally considered to suppress immunoinflammatory reactions at a number of levels. IL-10 pro-motes B-cell growth and immune responses mediated by B cells and their products; thus IL-10 has a wide-ranging action on the immune system and the importance of particular functions is likely to depend on the local context in which this cytokine is produced. 4 IL-10 is dysregulated in a number of pathological conditions including bacterial infections in man and in animal models. 6, 7 Significantly, local cytokine levels influence immune responses in PD, including the balance of T cell subsets and are therefore likely to be pathogenic factors in this disorder. 8 The IL-10 gene locus contains a number of single nucleotide polymorphisms (SNPs) and repeat unit polymorphisms which have been shown to be associated with a variety of diseases in which immune dysregulation contributes to pathogenesis. 9 Furthermore, in vitro studies indicate that particular combinations of haplotypes may influence directly IL-10 secretion. 10, 11 There is now evidence that polymorphisms in other cytokine genes are associated with both adult PD and EOP and may therefore contribute to genetic susceptibility in these disorders. 12, 13 In the present study we sought to investigate the possible association between the IL-10.G polymorphism and EOP.
EOP patients (n = 72) attending the periodontology clinics at Newcastle and Birmingham Dental Hospitals (UK) were recruited in accordance with the clinical criteria for EOP agreed by consensus at the World Workshop in Periodontics.
14 A subgroup (n = 21) of localised disease (L-EOP) was characterised using radiographic criteria as periodontal destruction (у3 mm bone loss) confined only to incisors and first molars and juxtaposed tooth surfaces. 15 The condition of EOP is clinically heterogenous, but within this broad condition, the sub-category of L-EOP is phenotypically highly defined. The present cross-sectional study addresses EOP, but data are analysed separately for L-EOP cases. Control subjects (n = 73) with no clinical evidence of periodontal diseases (probing attachment distances р1 mm from the cemento-enamel junction) were recruited from staff and other patients in the Dental Hospitals. All subjects were of white Caucasian heritage and free of systemic disease.
During the analysis of the IL-10.G genotypes in our patient and control groups we identified 10 alleles (G7 to G16) which correspond to structures containing 19 to 28 polymorphic CA repeats respectively ( Table 1 ). The remaining alleles (G1-6) are either rare in the population and/or merely presumed to exist on the basis of the sizes of the largest and smallest alleles thus far identified. 16 The allele frequencies and genotype distribution between the patient and control groups was compared using the 'Clump' software. 17 This programme has been designed for the analysis of disease associations at multi-allelic loci, such as the IL-10 microsatellites, and takes into account the presence of rare alleles. [17] [18] [19] The Clump package applies the Monte Carlo simulation to generate a 'T4' statistic which measures overall differences in the frequencies of all alleles simultaneously. In each analysis 1000 simulations were performed and a P value of Ͻ0.05 was considered significant.
There was no significant difference in the distribution of 
a Comparison of both EOP patients and L-EOP patients with healthy controls using the Monte Carlo simulation for alleles G7-G16 provided no evidence for significant differences allelic distribution (EOP vs controls: T4 = 7.071, P = 0.273; L-EOP vs controls: T4 = 8.976, P = 0.120).
b
The IL-10.G microsatellite genotype was determined by a fluorescence-based semi-automated genotyping method employing an ABI technology and Genescan and Genotyper software (PE applied Biosystems, Warrington, UK). Briefly, an approximately 180 bp fragment of the promoter region of the IL-10 gene spanning the IL-10.G polymorphism was amplified by PCR using one unlabelled and one FAM-fluorescently labelled primer corresponding to sequences in the promoter region: primer 1 upstream; 5Ј-AGCAACACTCCTCGTCGCAAC-3Ј and primer 2 downstream; 5Ј-GGAGGCTGGATAGGAGGTCCC-3Ј. PCR products were pooled with 2 × the volume of Tamra internal lane size standard (Prism ™ 500-Tamra, PE Applied Biosystems), formamide and dextran blue mix; denatured for 2 min at 94°C and subjected to high-resolution acrylamide gel electrophoresis on an ABI 373 DNA sequencer. DNA fragment data were collected and analysed employing Genescan and Genotyper software respectively. Sample genotypes, correlating to the number of (CA) repeats, were determined by comparison of PCR fragment sizes (allele peaks) to the internal lane size standard. PCR products from cloned and sequenced IL-10 PCR products corresponding to distinct IL-10.G alleles were included as control samples.
Genes and Immunity the IL-10.G alleles between the overall EOP group and the controls (Table 1) . Similar findings relating to an analysis of microsatellite polymorphisms in the IL-10 locus (both IL-10.G and IL.10 R) in patients from Glasgow with generalised-EOP (G-EOP) have been reported. 19 However our overall patient group, unlike the Glasgow cohort, includes patients with localised as well as generalised EOP. There was no difference in the overall allele distribution between L-EOP patients and controls (Table 1) .
Interestingly, the IL-10G.9 allele and the G.9/9 genotype were reported to be significantly reduced in patients with the autoimmune disease systemic lupus erythematosus (SLE) whereas the IL-10G.13 allele was significantly elevated in the same patients. 18 In addition, data from the Glasgow study indicated reduced frequency of the IL-10.G9 allele in G-EOP patients as compared to controls, although this was not considered to be statistically significant. 19 The results of our own study indicated numerical differences in the frequencies of certain IL-10.G alleles between both the EOP and the L-EOP groups and the controls although these differences were not statistically significant (Table 1 ). In particular the frequency of IL-10.G9 was increased to 64.3% in the L-EOP group as compared to 41.8% in the control group ( Table 1 ). The present study and that previously published from the Glasgow group 19 have been conducted using small patient cohorts and therefore must be regarded as preliminary. However, both studies do suggest trends towards association between different clinical sub-groups of EOP and the IL-10.G polymorphism (in particular the IL-10.G9 allele) and therefore it is reasonable to suggest that further studies using larger numbers of patient numbers are warranted.
Genetic associations could indicate that certain alleles of the IL-10 gene have a direct effect on IL-10 synthesis and hence on immune function and disease pathogenesis. In support of this hypothesis there is accumulating evidence that the synthesis and secretion of IL-10 in response to mitogen and endotoxin stimulation is genetically determined. 20, 21 Recent evidence suggests that certain alleles of the IL-10.G and IL-10.R dinucleotide repeat polymorphisms are associated with altered IL-10 secretion levels in response to standard stimuli. 10, 11 In particular a haplotype containing the IL-10.G14 allele was found to be associated with highest levels of IL10 secretion and a haplotype containing the IL-10.G7 allele was associated with lowest IL-10 secretion. 10 More recently detailed haplotypes for the polymorphisms in the IL-10 promoter have been defined; the G9 allele is associated with two of these four newly defined haplotypes. 11 Furthermore, data from in vitro assays indicate that IL-10 secretion levels may be differentially influenced by these haplotypes although there is a wide variation in individual secretion levels associated with particular haplotypes and no statistically significant differences between the four groups emerged. 11 There are other data which suggest that different alleles of certain SNPs within this locus may also influence IL-10 synthesis although the data are conflicting. Clearly it would be interesting to fully define the IL-10 gene haplotypes in our population and to relate these to IL-10 secretion levels.
These polymorphisms are located in the IL-10 gene promoter region close to the transcription initiation site and therefore in a region of potential regulatory significance. It is conceivable that the regulation of IL-10 transcription could be modified by local variations in chromosomal architecture due to different numbers of dinucleotide repeats at the IL-10.G polymorphism. Although the regulation of IL-10 gene transcription is not fully understood, it is clear that the promoter region of the IL-10 gene, encompassing the IL.1-10.G polymorphism, contains many potential transcription factor binding sites. 22, 23 IL-10 production is tightly regulated since very little constitutive expression of IL-10 occurs but the IL-10 promoter is responsive to a variety of stimuli in different microenvironments and cell types. 24 These findings emphasise the importance of induced transcription of IL-10 in immune functions.
An alternative explanation is that genetic associations may reflect an association between known and/or unknown genes in linkage with the IL-10 gene, rather than a direct effect of structural variation in the IL-10 locus itself. However, candidate genes sufficiently close to the IL-10 locus to allow for possible linkage disequilibrium have not yet been identified. The influential location of the IL-10.G polymorphism in the promoter region of the gene and the well-characterised role of IL-10 in pathogenesis of immune-mediated diseases support the hypothesis that polymorphisms in the IL-10 promoter have direct effects on disease pathogenesis. 22 Our previous work has indicated that SNPs in the IL-1␤ and vitamin D receptor (VDR) genes are associated with various clinical sub-groups of EOP indicating a role of genetic polymorphism in EOP. 13, 25 It is important to recognise that although genetic association studies are considered to be sensitive enough to detect genes with modest effect they are affected by differences between populations and population stratification. 26 Other problems with the design of genetic association studies include variability of results between studies due to weak effect on phenotype or weak linkage disequilibrium. 27 The results of the present study do not provide any evidence for a role of the IL-10.G microsatellite polymorphism in genetic susceptibility to EOP or L-EOP. There is clearly a requirement not only for genetic association studies of this kind to be repeated in similar, larger populations but furthermore the need for such studies to be carried out in the context of alternative genetic approaches such as family-based genetic studies. There is also a need to link the occurrence of genetic polymorphisms to functional assays of their biological effect and to equate these with measures of disease experience.
